News
SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.
Swipe to discover more
-
bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments). -
Knowledge of COVID-19 Helps Us Understand Viral Sepsis
As of early 2024, the World Health Organization (WHO) has reported over 700 million confirmed cases of COVID-19 worldwide. As scientists continue to study SARS-CoV-2 and its variants, they are gaining valuable insights into how viruses are transmitted, how they may lead to serious life-threatening conditions such as sepsis. -
Paris 2024: National teams choose bioMérieux’s BIOFIRE® PCR solutions to test athletes
During this summer's Olympic and Paralympic Games in Paris, several committees and national teams, including the Dutch delegation, will be using the BIOFIRE® range of PCR test solutions developed by bioMérieux to detect respiratory and gastrointestinal infections in their athletes.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19